About Biocon Ltd

Biocon Limited is India’s largest biopharmaceutical company with its head office in Bangalore, Karnataka, India. It was founded by current chairman, Ms. Kiran Mazumdar-Shaw, in 1978 as a joint venture with Biocon Biochemicals Ltd., an Irish company. Aside from offering research services, the company manufactures and sells small molecules (APIs), biosimilars, branded formulations and novel molecules to 100+ countries (65%) including India (35%).


The company’s business model spans across:


  • 5 key verticals:

    • Small Molecules (APIs)

    • Biosimilars

    • Branded Formulations

    • Novel Molecules

    • Research Services


  • The entire value chain, including:

    • Preclinical discovery– via Syngene International Limited

    • Clinical development – via Clinigene International Limited

    • Biopharmaceuticals – via Biocon Limited


In the fiscal year ending 31 March 2015, the company

  • Owned 7 subsidiary companies

  • Operated in the following segments:

    • Core Biopharma products, contributing 57% of total revenues

    • Branded Formulations, contributing 14% of total revenues

    • Research Services, contributing 26% of total revenues

    • Others, contributing 3% of total revenues

  • Had invested 10.4% of its annual revenues on R&D

  • Was the fourth largest insulin producer in the world (and the largest in India)

  • Focused primarily on chronic diseases like diabetes, cancer and autoimmune diseases



Biocon Limited is listed on the National Stock Exchange of India (NSE) and the Mumbai Stock Exchange (BSE).



Biocon Limited at-a-glance



  • Employees 7,500+
  • Turnover (31 March, 2015) ~USD 504 m
  • Subsidiaries 7
  • Patent Applications Filed 1241
  • Patents Granted 625
  • Registered Trademarks 450
  • Exports (countries) 100+







ISO 9001:2008
ISO 14001:2004
OHSAS 18001:2007
USFDA for GMP compliance
EUGMP for drug substances
COFEPRIS (Mexican Health Authority)
FDA (Korea)
FDA (Jordan)
FDA (Saudi Arabia)
FDA (Tanzania)
Iran (MOH)
ANVISA (Brazil)
Nepal Health Authority
Yemen Ministry of Health
Zimbabwe Ministry of Health
Ghana Ministry of Health
Kenya Ministry of Health
Ivory Coast Ministry of Health Malawi Ministry of Health Colombia Ministry of Health Schedule – M GMP Certification (as per D&C Act, India)




*Sources: Annual Report 2015, Factsheet





  • 1978 – Founded by Indian entrepreneur, Ms. Kiran Mazumdar-Shaw, as a joint venture with Biocon Biochemicals Ltd.


  • 1979 – Becomes the first Indian company to manufacture and export enzymes to Europe and USA


  • 1989 – Receives US funding for proprietary technologies


  • 1993 – Receives ISO 9001 certification from RWTUV, Germany for its R&D and manufacturing facilities


  • 1994 – Sets up a custom research company, Syngene International Pvt. Ltd., to meet R&D outsourcing needs


  • 1996

    • Expands proprietary fermentation plant capacity by 3-fold

    • Enters biopharmaceuticals and statins


  • 1998 – Biocon becomes an independent entity after buying Unilever’s shareholding in Biocon


  • 2000

    • Commissions a fully automated submerged fermentation plant to produce specialty pharmaceuticals

    • Establishes India's first Clinical Research Organization, Clinigene International Limited, to pursue clinical R&D


  • 2001

    • Becomes the first Indian company receive US FDA approval for manufacturing lovastatin, a cholesterol-lowering molecule, from solid state fermentation

    • Receives US 2001 and worldwide patent for proprietary bioreactor, PlaFractor™ 


  • 2002 – Receives CAP accreditation for Clinigene's clinical laboratory (the first in India to receive it)


  • 2003 – Becomes the first company in the world to develop human insulin on a Pichia expression system


  • 2004

    • Becomes the first Indian company to commercialize generic recombinant human insulin developed on proprietary fermentation technology

    • Launches a highly successful IPO – and becomes the second Indian company to cross the USD 1 billion mark on the first day of listing

    • Syngene International Limited establishes a new research center

    • Launches Insugen ®, a new generation bio-insulin

    • Forms broad strategic partnership with Vaccinex, Inc. to discover and co-develop at least four therapeutic antibody products


  • 2005 – Signs commercial agreement to supply insulin API to Asia, Africa and the Middle East.


  • 2006

    • Inaugurates India's largest multi-product Biologics facility at Biocon Park – Biocon Biopharmaceuticals

    • Inaugurates India's largest integrated biotechnology hub, the 90-acre Biocon Park, comprising a cluster of research labs and manufacturing facilities, Karnataka

    • Announces a licensing agreement with Bayer HealthCare (BHC) to exclusively market INSUGEN® in China

    • Concludes agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease with Innate Pharmaceuticals AB, Umea, Sweden through its subsidiary, Syngene International Limited

    • Launches India's first anti-cancer drug, BIOMAb EGFR®


  • 2007

    • Signs an MOU with Neopharma, an Abu Dhabi based pharmaceutical company to establish a JV to manufacture and market biopharmaceuticals for GCC countries

    • Grants exclusive license to Ferozsons Laboratories Limited to market BIOMAb EGFR® in Pakistan

    • Launches Nephrology Division and a comprehensive portfolio of renal therapy products

    • Enters into a research partnership with Bristol-Myers Squibb through Syngene International Limited

    • Signs MOU with Deakin University, Australia to establish Deakin Research Institute in Bangalore

    • Divests enzymes division for USD 115 million to Novozymes and decides to focus on biopharmaceuticals

    • Announces an agreement with Abraxis Biocon and Abraxis BioScience wherein the former will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and EU

    • Signs MOU with Neopharma to establish Neobiocon, a joint venture in Dubai

    • Announces a licensing agreement with Abraxis BioScience Inc. for the commercialization of ABRAXANE®


  • 2008

    • Acquires a 78% stake in a German pharmaceutical company, AxiCorp GmbH, for €30 Million

    • Launches a safety device for 2 life-saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc.

    • Launches ABRAXANE with Abraxis Bioscience in India for treatment of breast cancer

    • Named among the Top 20 Global Biotechnology Companies (Med Ad News)

    • Becomes the 7th Largest Biotech Employer in the World (Med Ad News)


  • 2009

    • Named among the Top 20 Indian companies in Forbes’ list of Best Under A Billion companies

    • Partners with Sapient Discovery (via Syngene International Ltd.) to expand integrated drug discovery offerings

    • Forges alliance partnership with DuPont Crop Protection via Syngene International Ltd.

    • Opens a new R&D Facility with Bristol-Myers Squibb at Biocon Park

    • Launches BASALOG – a long lasting basal insulin for Type 1 & Type 2 Diabetics

    • Partners with ISB to launch the Biocon Cell for Innovation Management

    • Announces strategic collaboration with Mylan to enter the global generic Biologics market

    • Enters into a global development and commercialization agreement with Amylin Pharmaceuticals for a novel peptide hybrid program to focus on diabetes treatment


  • 2010

    • Joins hands with Bayer to create self-monitoring awareness among diabetics

    • Joins hands with Endo Pharmaceuticals, USA through Syngene International Ltd. to discover and develop novel biological drug molecules to fight cancer

    • Acquires stake of its Cuban partner CIMAB S.A.

    • Announces manufacturing and supply agreement with Optimer Pharmaceuticals for a novel API and a first-in-class anti-infective (C. difficile)

    • Strengthens existing research partnership with Cuba-based Center of Molecular Immunology (CIM) for an integrated antibody program in immunology

    • Announces strategic foreign direct investment with Malaysian Biotechnology Corporation SdnBhd


  • 2011

    • Commences first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia

    • Launches INSUPen®, an affordable and convenient reusable insulin delivery device

  • 2012

    • Receives investment from GE Capital in Syngene International Limited

    • Announces positive efficacy data from Phase 3 clinical study with Novel Monoclonal Antibody, Itolizumab for Psoriasis

    • Sets up a dedicated Nutrition Research and Development Center at Biocon Park in a collaboration between Abbott and Syngene International Ltd.

    • Announces positive results from Phase 1 Comparative PK-PD Study with biosimilar Insulin Glargine

    • Becomes the only Asian Company to feature in the Global Top 20 BioPharma Employers (Science Magazine)

    • Enters into an agreement with Bristol-Myers Squibb for an Oral Insulin drug, IN-105


  • 2013

    • Receives marketing authorization from the Drugs Controller General of India (DCGI) for the treatment of chronic plaque Psoriasis

    • Enhances partnership with Mylan via strategic collaboration for Insulin products

    • Launches a first-in-class drug (ALZUMAb™) for novel biologic treatment of psoriasis in India

    • Partners with CytoSorbents to market CytoSorb® - a first-in-class therapy for managing Sepsis

    • Ranked 6 among Top 20 Global Biotech Employers by Science Magazine

    • Receives regulatory approval in India (along with Mylan) for treating breast cancer with Trastuzumab

    • Collaborates with Quark Pharmaceuticals to develop Novel siRNA based therapeutics

    • Biocon’s ALZUMAb™ wins BioSpectrum BioPharma Product of the Year award in 2013


  • 2014

    • Receives the Sir JC Bose Memorial Award – 2013 (Institutional Category) from Indian Science Monitor (ISM) for contribution in Biotechnology, with special reference to ALZUMAb (Itolizumab)

    • Launches CANMAb™ - the world’s most affordable trastuzumab for treating metastatic breast cancer in India

    • Sets up a dedicated R&D Center at Biocon Park through a collaboration between its subsidiary, Syngene International Ltd., and Baxter

    • Silver Leaf Oak (Mauritius) Limited agrees to acquire 10% stake in Biocon’s research subsidiary, Syngene International Limited, at a valuation of INR 3800 crore

    • Expands strategic partnership with CytoSorbents for CytoSorb® to treat SIRS and patients of cardiac surgery


  • 2015

    • Chairman Ms. Kiran Mazumdar-Shaw is featured on Forbes' 2015 list of 100 Most Powerful Women

    • Receives recognition for outstanding contribution to public health from WHO-India

    • Strengthens presence in Mexico and receives approval for Insulin Glargine through local partner, PiSA Farmaceutica

    • Syngene International Ltd., Biocon's custom research organization, lists on BSE and NSE, and is valued at $1 billion on market debut

    • Inaugurates world-class devices facility in Bangalore & introduces Basalog One™ in India

    • Becomes the only Asian company to be ranked among the Top 20 Global Biotech Employers in 2015


  • 2016

    • Announces data from key studies for Insulin Tregopil

    • Receives approval for first generic formulation in EU and is on track to launch Rosuvastatin Tablets in FY1

    • Signs co-development & commercialization agreement with Lab PiSA for rh-Insulin in USA

    • Receives regulatory approval in Japan for Insulin Glargine




  • Chairman & Managing Director: Ms. Kiran Mazumdar-Shaw

  • Vice Chairman, foreign Promoter & Whole-time Director: Mr. John Shaw

  • Chief Executive Officer & Joint Managing Director: Dr. Arun Chandavarkar

  • Non-Executive Directors: Mr. Daniel M. Bradbury, Ms. Mary Harney, Prof. Ravi Mazumdar, Mr. Russell Walls, Dr. Vijay Kuchroo, Dr. Jeremy Levin


Biocon Ltd Contact Details




20th KM, Hosur Road

Hebbagodi, Electronic City PO

Bangalore – 560 100

Karnataka, India


Contact: Tel +91 80 2808 2037

Email: kiran.kumar@biocon.com


Ms. Seema Ahuja

Head – Corporate Communications


Tel: 91 80 - 2808 2808

Email: seema.ahuja@biocon.com


Biocon Limited

485 Hwy 1 (S)

Suite B 305

Iselin, NJ 08830



Tel: (732) 636 2950

Fax: (732) 636 2951

Email: abhijit.zutshi@biocon.com


Biocon (London) Limited

50, Elm Quay Court

30, Nine Elms Lane

SW8 5DF, London



Email: nehal.vora@biocon.com



P.O. Box 72900

Abu Dhabi

United Arab Emirates


Tel: +971 -2- 6585 990

Fax: +971 -2- 6321 626

Email: info.neobiocon@biocon.com



NeoBiocon FZ LLC


P.O. Box 505176


United Arab Emirates


Tel: +971 -4- 454 1079

Fax: +971 -4- 454 1125

Email: info.neobiocon@biocon.com



* Indicates mandatory field.
Please wait while comments are being sent...